Inovio’s ebolavirus vaccine shows potential immune response in Phase 1b trial

Inovio announced that data from a Phase 1b trial evaluating INO-4201 as an Ebola booster vaccine candidate for rVSV-ZEBOV was presented at the 33rd European Congress of Clinical Microbiology and Infectious Diseases. "Preliminary data showed that INO-4201 was well tolerated and produced a strong immune response," said Dr. Huttner. "This suggests that a booster dose of IN0-4201 has the potential to extend protection against Ebola and could be an important tool in future Ebola Virus Disease prevention." In February 2023, Inovio announced positive initial results from the Phase 1b trial that evaluated INO-4201 as a booster in healthy adult participants who previously received a single injection of Ervebo. These initial results showed that INO-4201 was well-tolerated and boosted humoral responses in 100% of 36 treated participants. The full data was presented at ECCMID indicates the potential of INO-4201 to restore antibody titers to levels thought to be required to provide protection against Zaire ebolavirus infection. These new data include the assessment of binding antibodies showing that all 36 vaccine recipients responded to the boost. the Phase 1b trial for INOVIO’s vaccine candidate, INO-4201, was spearheaded by Global Urgent and Advanced Research and Development, sponsored by Geneva University Hospitals, and funded by the U.S. Defense Advanced Research Projects Agency.